Spelling suggestions: "subject:"diphtheria toxoid"" "subject:"diphtheria oxoid""
1 |
The present status of diphtheria immunization by one dose of alum precipitated toxoid a thesis submitted in partial fulfillment ... Master of Science in Public Health ... /Gold, Sidney H. January 1939 (has links)
Thesis (M.S.P.H.)--University of Michigan, 1939.
|
2 |
The present status of diphtheria immunization by one dose of alum precipitated toxoid a thesis submitted in partial fulfillment ... Master of Science in Public Health ... /Gold, Sidney H. January 1939 (has links)
Thesis (M.S.P.H.)--University of Michigan, 1939.
|
3 |
Schick test survey in preschoolers age 1-5 years Din Daeng Housing Project no. 6001-6003, Bangkok 1982 /Chusri Wongkruawan. January 1982 (has links) (PDF)
Thesis (M.Sc. (Public Health))--Mahidol University, 1982.
|
4 |
The preparation of diphtheria toxin, toxoid and antitoxin a thesis submitted in partial fulfillment ... Master of Science in Public Health ... /Ke, Fu-Chen. January 1937 (has links)
Thesis (M.S.P.H.)--University of Michigan, 1937.
|
5 |
The preparation of diphtheria toxin, toxoid and antitoxin a thesis submitted in partial fulfillment ... Master of Science in Public Health ... /Ke, Fu-Chen. January 1937 (has links)
Thesis (M.S.P.H.)--University of Michigan, 1937.
|
6 |
Chitosan derived formulations and EmzaloidTM technology for mucosal vaccination against diphtheria : oral efficacy in mice / Elaine van der WesthuizenVan der Westhuizen, Elaine January 2004 (has links)
Vaccination plays a very important part in daily life. It is essential to get vaccinated at an
early age. The conventional parented method used is not always effective and not cost
efficient. It requires qualified personnel and sterile conditions for administration of the
vaccines.
The aim of this study was to investigate the effect of chitosan, N-trimethyl chitosan
chloride (TMC) and Emzaloid™ particles on the local and systemic immune response of
mice after oral vaccination with Diphtheria toxoid (DT). The different formulations used
were chitosan microparticles (± 10 µm), chitosan nanoparticles (± 400 nm), TMC
microparticles (± 5 µm), Emzaloid microparticles (± 4 µm) and Emzaloid nanoparticles
(± 500 nm). All of these formulations proved to be very good delivery systems and can
entrap large amounts of the antigen.
Balb/c mice were used to determine the local and systemic immune response of these
formulations. The mice were vaccinated orally on three consecutive days in week 1 and
3 with 40 Lf DT per week with a total volume of 300 µl. Blood samples were taken from
the mice and analysed for a systemic immune response (IgG). The same mice were used
to determine the local immune response (IgA). Faeces were collected from each mouse
on day 1, 3, 4, 6, 14 and 20 for analysis. An enzyme-linked immunosorbent assay
(ELISA) was used to determine IgG and IgA titers.
It can be concluded that chitosan nanoparticles was the only formulation with a higher
response than that of the currently used vaccine. Emzaloid nanoparticles showed no
significant difference in response when compared to the currently used vaccine. All the
other formulations showed a much smaller response than that of the conventional method
of vaccination. / Thesis (M.Sc. (Pharmaceutics))--North-West University, Potchefstroom Campus, 2005.
|
7 |
Chitosan derived formulations and EmzaloidTM technology for mucosal vaccination against diphtheria : oral efficacy in mice / Elaine van der WesthuizenVan der Westhuizen, Elaine January 2004 (has links)
Vaccination plays a very important part in daily life. It is essential to get vaccinated at an
early age. The conventional parented method used is not always effective and not cost
efficient. It requires qualified personnel and sterile conditions for administration of the
vaccines.
The aim of this study was to investigate the effect of chitosan, N-trimethyl chitosan
chloride (TMC) and Emzaloid™ particles on the local and systemic immune response of
mice after oral vaccination with Diphtheria toxoid (DT). The different formulations used
were chitosan microparticles (± 10 µm), chitosan nanoparticles (± 400 nm), TMC
microparticles (± 5 µm), Emzaloid microparticles (± 4 µm) and Emzaloid nanoparticles
(± 500 nm). All of these formulations proved to be very good delivery systems and can
entrap large amounts of the antigen.
Balb/c mice were used to determine the local and systemic immune response of these
formulations. The mice were vaccinated orally on three consecutive days in week 1 and
3 with 40 Lf DT per week with a total volume of 300 µl. Blood samples were taken from
the mice and analysed for a systemic immune response (IgG). The same mice were used
to determine the local immune response (IgA). Faeces were collected from each mouse
on day 1, 3, 4, 6, 14 and 20 for analysis. An enzyme-linked immunosorbent assay
(ELISA) was used to determine IgG and IgA titers.
It can be concluded that chitosan nanoparticles was the only formulation with a higher
response than that of the currently used vaccine. Emzaloid nanoparticles showed no
significant difference in response when compared to the currently used vaccine. All the
other formulations showed a much smaller response than that of the conventional method
of vaccination. / Thesis (M.Sc. (Pharmaceutics))--North-West University, Potchefstroom Campus, 2005.
|
8 |
Chitosan derived formulations and EmzaloidTM technology for mucosal vaccination against diphtheria : nasal efficacy in mice / Erika M. TruterTruter, Erika Mare January 2005 (has links)
Previous studies have demonstrated that chitosan and its derivative, N-trimethyl chitosan
chloride (TMC) are effective and safe absorption enhancers to improve mucosal delivery
of macromolecular drugs including vaccines. Furthermore, chitosan and TMC can easily
form microparticles and nanoparticles, which have the ability to encapsulate large
amounts of antigens. Emzaloid™ technology has proven in the past to be an effective
delivery system for numerous drugs. Emzaloids can entrap, transport and deliver large
amounts of drugs including vaccines.
In this study, the ability of chitosan microparticles and nanoparticles, TMC microparticles
as well as micrometer and nanometer range Emzaloids to enhance both the systemic and
mucosal (local) immune response against diphtheria toxoid (DT) after nasal
administration in mice was investigated.
The above mentioned formulations were prepared and characterised according to size and
morphology. DT was then associated to the chitosan microparticles and nanoparticles as
well as TMC microparticles to determine the antigen loading and release. It was found
that the loading efficacy of the formulations was 88.9 %, 27.74 % and 63.1 %
respectively, and the loading capacity of the formulations was 25.7 %, 8.03 % and
18.3 %.
DT loaded and unloaded (empty) chitosan microparticles and nanoparticles, TMC
microparticles, micrometer and nanometer range Emzaloids as well as DT in phosphate
buffered saline (PBS) were administered nasally to mice. Mice were also vaccinated
subcutaneous with DT associated to alum as a positive control. All mice were vaccinated
on three consecutive days in week 1 and boosted in week 3. Sera was analysed for anti-
DT IgG and nasal lavages were analysed for anti-DT IgA using an enzyme linked
imrnunosorbent assay (ELISA).
In the study conducted to determine the systemic (IgG) and local (IgA) immune
responses it was seen that DT associated to all the experimental formulations produced a
systemic immune response. The said formulations produced a significantly higher
systemic immune response when compared to the formulation of DT in PBS.
Furthermore, the mice vaccinated with DT associated to the TMC formulations showed a
much higher systemic immune response than the mice that were vaccinated
subcutaneously with DT associated to alum, whereas the other formulations produced
systemic immune responses that were comparable to that of DT associated to alum. It was
also found that DT associated to the experimental formulations produced a local immune
response, however only DT associated to TMC microparticles produced a consistent local
immune response.
It can be concluded from the in vivo experiments that the TMC formulations, moreover,
the TMC microparticles is the most effective and promising formulation for the nasal
delivery of vaccines. / Thesis (M.Sc. (Pharmaceutics))--North-West University, Potchefstroom Campus, 2005.
|
9 |
Chitosan derived formulations and EmzaloidTM technology for mucosal vaccination against diphtheria : nasal efficacy in mice / Erika M. TruterTruter, Erika Mare January 2005 (has links)
Previous studies have demonstrated that chitosan and its derivative, N-trimethyl chitosan
chloride (TMC) are effective and safe absorption enhancers to improve mucosal delivery
of macromolecular drugs including vaccines. Furthermore, chitosan and TMC can easily
form microparticles and nanoparticles, which have the ability to encapsulate large
amounts of antigens. Emzaloid™ technology has proven in the past to be an effective
delivery system for numerous drugs. Emzaloids can entrap, transport and deliver large
amounts of drugs including vaccines.
In this study, the ability of chitosan microparticles and nanoparticles, TMC microparticles
as well as micrometer and nanometer range Emzaloids to enhance both the systemic and
mucosal (local) immune response against diphtheria toxoid (DT) after nasal
administration in mice was investigated.
The above mentioned formulations were prepared and characterised according to size and
morphology. DT was then associated to the chitosan microparticles and nanoparticles as
well as TMC microparticles to determine the antigen loading and release. It was found
that the loading efficacy of the formulations was 88.9 %, 27.74 % and 63.1 %
respectively, and the loading capacity of the formulations was 25.7 %, 8.03 % and
18.3 %.
DT loaded and unloaded (empty) chitosan microparticles and nanoparticles, TMC
microparticles, micrometer and nanometer range Emzaloids as well as DT in phosphate
buffered saline (PBS) were administered nasally to mice. Mice were also vaccinated
subcutaneous with DT associated to alum as a positive control. All mice were vaccinated
on three consecutive days in week 1 and boosted in week 3. Sera was analysed for anti-
DT IgG and nasal lavages were analysed for anti-DT IgA using an enzyme linked
imrnunosorbent assay (ELISA).
In the study conducted to determine the systemic (IgG) and local (IgA) immune
responses it was seen that DT associated to all the experimental formulations produced a
systemic immune response. The said formulations produced a significantly higher
systemic immune response when compared to the formulation of DT in PBS.
Furthermore, the mice vaccinated with DT associated to the TMC formulations showed a
much higher systemic immune response than the mice that were vaccinated
subcutaneously with DT associated to alum, whereas the other formulations produced
systemic immune responses that were comparable to that of DT associated to alum. It was
also found that DT associated to the experimental formulations produced a local immune
response, however only DT associated to TMC microparticles produced a consistent local
immune response.
It can be concluded from the in vivo experiments that the TMC formulations, moreover,
the TMC microparticles is the most effective and promising formulation for the nasal
delivery of vaccines. / Thesis (M.Sc. (Pharmaceutics))--North-West University, Potchefstroom Campus, 2005.
|
10 |
REVs-Chi: um novo sistema particulado para encapsulação de macromoléculas terapêuticas / REVs-Chi: A new particulate system for encapsulation of therapeutic macromoleculesRescia, Vanessa Cristina [UNIFESP] 29 July 2009 (has links) (PDF)
Made available in DSpace on 2015-07-22T20:50:47Z (GMT). No. of bitstreams: 0
Previous issue date: 2009-07-29 / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) / Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) / Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) / A quitosana (Chi), a (1-4)-amino-2-desoxi-ƒÒ-glicana, e a forma desacetilada da quitina, um polissacarideo das conchas de crustaceos. As suas caracteristicas unicas como a carga positiva, biodegradabilidade, biocompatibilidade, atoxicidade e estrutura rigida fazem com que esta macromolecula seja ideal para uso como sistema oral de entrega de vacinas. Foram preparadas vesiculas unilamelares grandes (REVs) envoltas por dentro e por fora (como um sanduiche) com quitosana (Chi) e poli-vinil alcool (PVA). Entretanto, existem alguns problemas as serem superados com relacao a estabilizacao da proteina durante este processo. Durante a fase de formacao de micelas reversas, no processo de nanoencapsulacao da proteina, expandem-se as interfaces hidrofobicas que entao levam as adsorcoes interfaciais seguidas por desenovelamento e agregacao das proteinas. Aqui, observaram-se atraves de tecnicas espectroscopicas e imunologicas, o uso dos sais da serie de Hoffmeister durante a fase de formacao de micela reversa para estudar a conformacao estavel do toxoide difterico (Dtxd). Foi estabelecida uma correlacao entre os sais usados na fase aquosa e as variacoes na solubilidade e conformacao de Dtxd. Como o conteudo em helice-ƒÑ foi praticamente estavel concluiu-se que a encapsulacao de Dtxd ocorreu sem agregacao ou sem exposicao de residuo hidrofobico na proteina. A agregacao de Dtxd foi evitada em 98 % quando se usou o cosmotropico PO2-4. Este ion foi usado para se preparar uma formulacao de Dtxd em REVs-Chi-PVA estavel e com identidade imunologica reconhecida na presenca de PO2-4. Entao, obteve-se uma solubilidade e estabilidade maxima de Dtxd depois de seu contacto com CH3CO2C2H5 para comecar a sua nanoencapsulacao em condicoes ideais. Este foi um avanco tecnologico importante porque uma solucao simples, como e a adicao de sais, evitou o uso de proteinas heterologas (Rescia et alii, 2009a). A proteina estabilizada foi entao encapsulada dentro de REVs como o descrito. Os lipossomas tem sido descritos como adjuvantes desde 1974 (Allison e Gregoriadis, 1974). A maior limitacao de seu uso em vacinas orais e a sua instabilidade estrutural causada pelas atividades enzimaticas do meio. O objetivo aqui foi combinar lipossomas, que podem encapsular antigenos (Dtxd, Diphtheria toxoid) com quitosana que protege estas particulas e promove a mucoadesibilidade. Empregaram-se tecnicas fisicas para se entender o processo pelo qual lipossomas (SPC: Cho, 3: 1) podem ser recobertos (interna e externamente) com quitosana (Chi) e PVA (poly-vinilic-alcohol) que sao polimeros biodegradaveis e biocompativeis. Obtiveram-se particulas de REVs-Chi (vesiculas preparadas por evaporacao de fase reversa recobertas interna e externamente com Chi) redondas e com as superficies rugosas e estabilizadas ou nao com PVA. As eficiencias de encapsulacao (Dtxd foi usada como antigeno) foram diretamente dependentes da presenca de Chi e PVA na formulacao. A adsorcao de Chi a superficie de REVs foi acompanhada por um aumento no potencial ƒê. Em contraste, a adsorcao de PVA a surperficie de REVs-Chi foi acompanhada por uma diminuicao do potencial . A presenca de Dtxd aumentou a eficiencia de adsorcao de Chi as superficies. A afinidade de PVA pela mucina foi 2000 vezes maior do que a observada somente com Chi e nao depende se a molecula esta em solucao ou se esta adsorvida a superficie lipossomal. A liberação do Dtxd foi retardada por sua encapsulação dentro de REVs-Chi-PVA. Concluiu-se que estas novas vesículas estabilizadas foram hábeis em se adsorverem às superfícies intestinais, resistiram às degradações e controlaram a liberação do antígeno. Assim, as partículas de REVs-Chi-PVA podem ser usadas como um veículo oral com capacidade adjuvante (Rescia et alii, 2009b). Os lipossomas revstidos por quitosana (REVs-Chi) como veículos orais para transporte de vacinas foram bem caraterizados neste laboratório. Estas partículas foram desenhadas para serem capturadas pelo muco, para interagirem com surperfícies orais e para resistirem às enzimas do trânsito gástrico. Foram usadas três formulações diferentes contendo o Dtxd (toxoide diftérico) para imunizar camundongos: REVs [Vesículas unilamelares obtidas por evaporação de fase reversa produzidas com SPC: Cho (3:1)]; REVs-Chi (REVs recobertas por Chi) e REVs-Chi-PVA (REVs recobertas por Chi e estabilizadas por PVA). Através do teste de adesibilidade e dos experimentos com anti-toxoide diftérico observou-se que houve uma correlação direta entre a complexidade da partícula (antígeno livre < REVs < REVs-Chi < REVs-Chi-PVA) e a produção de anticorpos (IgA, IgG1 and IgG2a) em todos os ensaios (R= 0,91766- 0,99718). O resultado mais interessante foi a total ausência da produção de IgA nos camundongos imunizados com o antígeno livre, provando então a excelência das partículas engenheiradas. Além do aumento da produção dos anticorpos de mucosa, ambas formulações com Chi ou com Chi-PVA estimularam tanto a produção de anticorpos humorais quanto a seletividade. Demonstrou-se que é possível de se estabelecer uma correlação entre REVs-Chi/Dtxd and REVs-Chi-PVA/Dtxd e o aumento da imunidade de mucosa. Estas partículas podem ser usadas como veículo geral tanto para transporte de drogas quanto de vacinas (Rescia et alli, 2009c). / Chitosan, - (1-4)-amino-2-deoxy-D-glucan) is a deacetylated form of chitin, a polysaccharide from crustacean shells. Its unique characteristics such as positive charge, biodegradability, biocompatibility, non-toxicity, and rigid structure make this macromolecule ideal for oral vaccine delivery system. We prepared reverse phase evaporation vesicles (REVs) sandwiched by chitosan (Chi) and polyvinylic alcohol (PVA). However, in this method there are still some problems to be circumvented related to protein stabilization. During the inverted micelle phase of protein nanoencapsulation, hydrophobic interfaces are expanded leading to interfacial adsorption followed by protein unfolding and aggregation. Here, spectroscopic and immunological techniques were used to ascertain the effects of the Hoffmeister series ions on Diphtheria toxoid (Dtxd) stability during the inverted micelle phase. A correlation was established between the salts used in aqueous solutions and the changes in Dtxd solubility and conformation. Dtxd α-helical content was quite stable what led us to conclude that encapsulation occurred without protein aggregation or without exposition of hydrophobic residues. Dtxd aggregation was 98 % avoided by the kosmotropic PO2-4. This ion was used to prepare a stable Dtxd and immunologically recognized REVs-Chi-PVA formulation in the presence of 50 mM PO42-. Under these conditions the Dtxd retained its immunological identity. Therefore, we could obtain the maximum Dtxd solubility and stability after contact with CH3CO2C2H5 to begin its nanoencapsulation within ideal conditions. This was a technological breakthrough because a simple solution like salt addition avoided heterologous proteins usage (Rescia et al., 2009a). The stabilized protein was as encapsulated within REVs as described. Liposomes have been used as adjuvants since 1974 (Allison and Gregoriadis, 1974). One major limitation for the use of liposomes in oral vaccines is the lipid structure instability caused by enzyme activities. Our goal was to combine liposomes which can encapsulate antigens (Dtxd, diphtheria toxoid) with chitosan which protects the particles and promotes mucoadhesibility. We employed physical techniques to understand the process by which liposomes (SPC: Cho, 3:1) can be sandwiched with chitosan (Chi) and stabilized by PVA (Poly-vinylic alcohol) which are biodegradable and biocompatible polymers. Round and smooth surfaced particles of REVs-Chi (Reversed phase vesicles sandwiched by Chi) stabilized by PVA were obtained. The REVs encapsulation efficiencies (Dtxd was used as the antigen) were directly dependent on the Chi and PVA present in the formulation. Chi adsorption on REVs surface was accompanied by an increase of  otential. In contrast, PVA adsorption on REVs-Chi surface was accompanied by a decrease of potential. The presence of Dtxd increased the Chi surface adsorption efficiency. The PVA affinity by mucine was 2000 higher than that observed with Chi alone and did not depend on the molecule being in solution or adsorbed on the liposomal surface. The liberation of encapsulated Dtxd was retarded by encapsulation within REVs-Chi-PVA. These results lead us to conclude that these new and stabilized particles were to able to adsorb to intestinal surfaces, resisted degradation and controlled the antigen release. Therefore, REVs-Chi-PVA particles can be used as an oral delivery adjuvant (Rescia et al., 2009b). Liposomes sandwiched by chitosan (REVs-Chi) as vehicles for oral vaccines have been well characterized in our laboratory. These particles were designed to be captured by mucus, to interact with oral surfaces and to withstand the enzymes of the gastric transit. Three different formulations containing Dtxd (diphtheria toxoid): REVs [reverse phase evaporation vesicles of SPC: Cho (3: 1)]; REVs-Chi (REVs sandwiched by chitosan) and REVs-Chi-PVA were used to immunize mice. Through adhesibility assays and antibody anti-diphtheria experiments we observed a direct correlation between particle complexity (free antigen < REVs < REVs-Chi < REVs-Chi-PVA) and antibody production (IgA, IgG1 and IgG2a) in all the assays (R= 0,91766- 0,99718). The most striking result was the absence of IgA production in those mice immunized with the free antigen, proving the excellence of the engineered particles. In addition to enhancement of mucosal antibodies production, the formulations with Chi and PVA stimulated both, humoral antibody production and selectivity. We have shown that it was possible to establish a correlation between REVs-Chi/Dtxd and REVs-Chi-PVA/Dtxd and the enhancement of mucosal immunity. These particles can be used as a general vehicle for oral drug or vaccine delivery systems (Rescia et al., 2009c). / TEDE / BV UNIFESP: Teses e dissertações
|
Page generated in 0.0613 seconds